A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Phase 2TerminatedNCT00069849

Abbott64 enrolled

Overview

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Alzheimer's Disease

Interventions

ABT-089DRUG

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

INCLUSION CRITERIA: * Current diagnosis of probable Alzheimer's disease. * ADAS-cog score of at least 12 and MMSE score of 10 to 26. * Non-smoker * Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person. * Fluent in English. EXCLUSION CRITERIA: * Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks. * Has clinically significant or uncontrolled medical condition other than Alzheimer's disease. * Nursing home resident.

Locations (8)

Unnamed facility

Fresno, California, United States

Unnamed facility

San Diego, California, United States

Unnamed facility

Orlando, Florida, United States

Unnamed facility

West Palm Beach, Florida, United States

Outcomes

Primary Outcomes

MMSE

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.